ReFineDR: Observational study of Routine ophthalmological tests of patients included in the two Phase 3 clinical trials, promoted by Bayer, FIDELIO and FIGARO to investigate the effect of Fineronone in delaying the progression of Retinop
COMMERCIAL POST AUTHORIZATION STUDY
Clinical trial information
- Promoter: BAYER AG
- Execution start: 17/09/2020
- End of execution: 30/03/2021
- PI: JUAN DIEGO MEDIAVILLA GARCIA